Innocan Pharma Secures C$462,477 in Private Placement

Each unit consists of one common share and a purchase warrant allowing the holder to acquire an additional share at C$2.50. These warrants remain valid for three years, though the company retains the right to accelerate the expiry date if the volume-weighted average price of its common shares hits or exceeds C$4.80 for 30 consecutive trading days.

To facilitate the offering, Innocan compensated arm's length finders with a 10% cash fee and issued 8% finder's warrants. The securities issued under this tranche are subject to a standard four-month-and-one-day hold period under Canadian securities regulations. The company, which operates its wellness segment primarily through its 60% owned subsidiary BI Sky Global Ltd., confirmed that these securities are not registered for sale within the United States.